Metformin treatment is associated with reduced risk of hypoglycaemia, major adverse cardiovascular events, and all-cause mortality in patients with post-pancreatitis diabetes mellitus: a nationwide cohort study
Authors' conclusion
Metformin is associated with a lower risk of adverse outcomes, including all-cause mortality in patients with PPDM, supporting the use of metformin as a glucose-lowering therapy for these patients.
Study context
- Population
- Danish adults (≥18 years) with incident post-pancreatitis diabetes mellitus (PPDM) or T2D, 2009–2018; PPDM categorised into acute (PPDM-A) and chronic (PPDM-C) subtypesPPDM
- Participants
- 3,781 adults
- Exposure
- Metformin treatment vs no metformin treatment
- Outcome
- Severe hypoglycaemia, major adverse cardiovascular events (MACE) and all-cause mortality in patients with PPDM
Methodological detailsnationwide, pharmaco-epidemiologic, time-varying exposures, Cox regression
- Nationwide
- Pharmaco-epidemiologic
- Time-varying exposures
- Cox regression
Main finding
As reported in the abstract
Severe hypoglycaemia, MACE and all-cause mortality in PPDM
Each group vs no metforminEstimate (95% CI)P value
Metformin
aHR (severe hypoglycaemia) 0.41(0.27–0.62)
P < 0.0001Metformin
HR (MACE) 0.74(0.60–0.92)
P = 0.0071Metformin
HR (all-cause mortality) 0.56(0.49–0.64)
P < 0.0001Observational data: associations, not effects.
Further findings
- Metformin treatment exhibited comparable trends of risk reduction in sensitivity analyses and in T2D
Original publication
Metformin treatment is associated with reduced risk of hypoglycaemia, major adverse cardiovascular events, and all-cause mortality in patients with post-pancreatitis diabetes mellitus: a nationwide cohort study. Eur J Endocrinol. Published 22 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →